Skip to main content

Paul Joseph Mosca, MD, PhD, MBA

Associate Professor of Surgery
Office: 10 Bryan Searle Drive, 466G Seeley G. Mudd Bldg, Durham, NC 27710
Campus Mail: DUMC 3966, 10 Bryan Searle Dr, 466G Seeley G Mudd, Durham, NC 27710

My research focuses on three areas. One is the development of more effective and entirely novel treatments for melanoma. I have a special interest in immunotherapy, novel targeted molecular therapies, and regional chemotherapy for advanced melanoma of the arm or leg. Another area of interest is palliative surgery for cancer with an emphasis on understanding the optimal role and application of this type of surgery in the care of advanced malignancy. A third area of interest is quality and patient safety with an emphasis on communication and work culture.

Education and Training

  • Assistant Professor, Surgery, Lehigh Valley Health Network, 2004 - 2010
  • Assistant Professor, Surgery, Duke University School of Medicine, 2002 - 2004
  • Chief Resident, Surgery, Duke University, 2001 - 2002
  • 2nd Year SAR, Surgery, Duke University, 2000 - 2001
  • Surgical Research Fellow, Surgery, Duke University, 1998 - 2000
  • Senior Assistant Resident, Surgery, Duke University, 1997 - 1998
  • Junior Assistant Resident, Surgery, Duke University, 1996 - 1997
  • Intern, Surgery, Duke University, 1995 - 1996
  • M.B.A., Desales University, 2011
  • M.D., University of Virginia, 1995
  • Ph.D., University of Virginia, 1994

Publications

Clay, T. M., A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse. “Assays for monitoring cellular immune responses to active immunotherapy of cancer.” Clin Cancer Res 7, no. 5 (May 2001): 1127–35.

Scholars@Duke

Morse, M. A., T. M. Clay, A. C. Hobeika, P. J. Mosca, and H. K. Lyerly. “Monitoring cellular immune responses to cancer immunotherapy.” Curr Opin Mol Ther 3, no. 1 (February 2001): 45–52.

Scholars@Duke

Hobeika, A. C., T. M. Clay, P. J. Mosca, H. K. Lyerly, and M. A. Morse. “Quantitating therapeutically relevant T-cell responses to cancer vaccines.” Crit Rev Immunol 21, no. 1–3 (2001): 287–97.

Scholars@Duke

Morse, M. A., S. Nair, M. Fernandez-Casal, Y. Deng, M. St Peter, R. Williams, A. Hobeika, et al. “Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.” J Clin Oncol 18, no. 23 (December 1, 2000): 3883–93. https://doi.org/10.1200/JCO.2000.18.23.3883.

Full Text

Mosca, P. J., A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, D. A. Caron, H. K. Lyerly, and M. A. Morse. “Multiple signals are required for IL-12 production by Flt-3 ligand mobilized dendritic cells.” In Blood, 96:295A-295A. AMER SOC HEMATOLOGY, 2000.

Scholars@Duke

Mosca, P. J., A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, M. A. Morse, and H. K. Lyerly. “A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment.” Blood 96, no. 10 (November 15, 2000): 3499–3504.

Scholars@Duke

Pages